Human medicines European public assessment report (EPAR): Cholib, fenofibrate,simvastatin, Date of authorisation: 26/08/2013, Revision: 19, Status: Authorised

Human medicines European public assessment report (EPAR): MabThera, rituximab, Date of authorisation: 02/06/1998, Revision: 65, Status: Authorised

Human medicines European public assessment report (EPAR): Abrysvo, respiratory syncytial virus vaccine (bivalent, recombinant), Date of authorisation: 23/08/2023, Revision: 16, Status: Authorised

Human medicines European public assessment report (EPAR): Breyanzi, lisocabtagene maraleucel, Date of authorisation: 04/04/2022, Revision: 12, Status: Authorised

Human medicines European public assessment report (EPAR): Idacio, adalimumab, Date of authorisation: 02/04/2019, Revision: 16, Status: Authorised

Human medicines European public assessment report (EPAR): Firazyr, icatibant, Date of authorisation: 11/07/2008, Revision: 29, Status: Authorised

Human medicines European public assessment report (EPAR): Tepkinly, epcoritamab, Date of authorisation: 22/09/2023, Revision: 8, Status: Authorised

Human medicines European public assessment report (EPAR): Comirnaty, COVID-19 mRNA vaccine, Date of authorisation: 21/12/2020, Revision: 63, Status: Authorised

Human medicines European public assessment report (EPAR): Cibinqo, abrocitinib, Date of authorisation: 09/12/2021, Revision: 17, Status: Authorised

Human medicines European public assessment report (EPAR): Ozawade, pitolisant, Date of authorisation: 01/09/2021, Revision: 7, Status: Authorised